Deadline: 24-Apr-23
The Biotechnology Industry Research Assistance Council (BIRAC) has announced the Proposals for Under National Biopharma Mission, an Industry-Academia Collaborative Mission for Accelerating Discovery Research to Early Development for Biopharmaceuticals – “Innovate in India (i3) Empowering biotech entrepreneurs & accelerating inclusive innovation”, also referred to as National Biopharma Mission (NBM).
Key Features of the Call
- This program is to seek Request for Proposals (RFP) for supporting –
- Development of products active against sensitive and drug resistant microbial pathogens mentioned in the Indian Priority Pathogen list (mainly, E. coli, Klebsiella Pneumoniae, Acinetobacter baumanii, Pseudomonas aeruginosa, Staphylococcus aureus, carbapenem resistant Enterobacteriaceae (CRE). The products should have established proof of principle including but not limited to the following -:
- New Chemical Entities or antibiotics from a new class with a novel mechanism of action (first in class), or pre-existing class of drugs (best in class), Repurposed Drugs, Combination with existing drugs
- Therapeutics which may be broad-spectrum or pathogen-specific antimicrobial Peptides, genetically-engineered antibodies, Immunomodulators, molecules that modulate virulence or pathogenicity, Microbiome modulating agents, bacteriophage therapies
- Development of products active against sensitive and drug resistant microbial pathogens mentioned in the Indian Priority Pathogen list (mainly, E. coli, Klebsiella Pneumoniae, Acinetobacter baumanii, Pseudomonas aeruginosa, Staphylococcus aureus, carbapenem resistant Enterobacteriaceae (CRE). The products should have established proof of principle including but not limited to the following -:
Scope of the Call
- The diagnostic should have demonstrated proof of concept (Completed TRL-3 stage as per BIRAC TRL definitions
- The diagnostic should detect at least one and preferably two of the critical bacterial pathogens as prioritized in the Indian Priority Pathogen List developed by WHO India and the Department of Biotechnology, Govt. of India, and/or test their susceptibility profiles
- The areas of support may include validation of prototypes or production technologies; adaptation of products or platform technologies to new applications; manufacturing and scale- up for deployment
- The diagnostic should fulfil at least one or more of the following criteria:
- Rapid detection test (with test time of <4 hours) that differentially detect and identify species
- Culture-independent and should focus on direct detection of the target pathogen(s) from primary samples
- Point-of-Care Tests/kits (POCT) that can be manufactured at large scale.
Eligibility Criteria
- The proposals can be submitted:
- Solely by Indian Company / LLP/ Non-profit organizations/ Society/ Trusts/ Foundation/ Associations/ Government entities/ Institutes/ R&D Organizations/ which is a legal entity OR
- Jointly by Indian Companies/ Non-profit organizations / LLP/ Society/ Trusts/ Foundation/ Associations/ Government entities/ Institutes/ R&D Organizations/ OR
- By an Industry-academia consortium of Indian Company/ Non-profit organizations/ LLP/ Society/ Trusts/ Foundation/ Association/ Government entities/ Institutes/ R&D Organizations
- Indian Start-up companies in collaboration with Industry/Academia/research institutes/ are specially encouraged to apply.
For more information, visit BIRAC.
